Cargando…
A Six-Gene Risk Model Based on the Immune Score Reveals Prognosis in Intermediate-Risk Acute Myeloid Leukemia
Tumor microenvironment (TME) has been revealed as an important determinant of diagnosis and treatment response in AML patients. The scores of immune and stromal cell scores of AML in the intermediate-risk group from The Cancer Genome Atlas (TCGA) database were calculated using the Estimation of STro...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076319/ https://www.ncbi.nlm.nih.gov/pubmed/35528167 http://dx.doi.org/10.1155/2022/4010786 |
_version_ | 1784701896306458624 |
---|---|
author | Lu, Cong Hu, Dong Zheng, Jin'e Cao, Shiyi Zhu, Jiang Chen, Xiangjun Huang, Shiang Yao, Junxia |
author_facet | Lu, Cong Hu, Dong Zheng, Jin'e Cao, Shiyi Zhu, Jiang Chen, Xiangjun Huang, Shiang Yao, Junxia |
author_sort | Lu, Cong |
collection | PubMed |
description | Tumor microenvironment (TME) has been revealed as an important determinant of diagnosis and treatment response in AML patients. The scores of immune and stromal cell scores of AML in the intermediate-risk group from The Cancer Genome Atlas (TCGA) database were calculated using the Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data algorithm. Differentially expressed genes were identified between high and low scores. Gene set enrichment and pathway analyses were performed. A risk score model based on TME for six immune-related genes was established and validated. Patients with a lower immune score had a longer overall survival than those with a higher score (P = 0.044). A total of 805 intersected genes as differentially expressed genes were identified and selected according to the comparison of both immune and stromal scores. The functional enrichment analysis shows that these genes are mainly associated with the immune/inflammatory response. The risk score model based on TME for six immune-related genes (including MEF2C, ENPP2, FAM107A, CD37, TNFAIP8L2, and CASS4) was established and validated in the TCGA database and well validated in the TARGET database (P = 0.005). A key microenvironment-related gene signature was identified that affects the outcomes of AML patients in the intermediate-risk group and might serve as therapeutic targets. |
format | Online Article Text |
id | pubmed-9076319 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-90763192022-05-07 A Six-Gene Risk Model Based on the Immune Score Reveals Prognosis in Intermediate-Risk Acute Myeloid Leukemia Lu, Cong Hu, Dong Zheng, Jin'e Cao, Shiyi Zhu, Jiang Chen, Xiangjun Huang, Shiang Yao, Junxia Biomed Res Int Research Article Tumor microenvironment (TME) has been revealed as an important determinant of diagnosis and treatment response in AML patients. The scores of immune and stromal cell scores of AML in the intermediate-risk group from The Cancer Genome Atlas (TCGA) database were calculated using the Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data algorithm. Differentially expressed genes were identified between high and low scores. Gene set enrichment and pathway analyses were performed. A risk score model based on TME for six immune-related genes was established and validated. Patients with a lower immune score had a longer overall survival than those with a higher score (P = 0.044). A total of 805 intersected genes as differentially expressed genes were identified and selected according to the comparison of both immune and stromal scores. The functional enrichment analysis shows that these genes are mainly associated with the immune/inflammatory response. The risk score model based on TME for six immune-related genes (including MEF2C, ENPP2, FAM107A, CD37, TNFAIP8L2, and CASS4) was established and validated in the TCGA database and well validated in the TARGET database (P = 0.005). A key microenvironment-related gene signature was identified that affects the outcomes of AML patients in the intermediate-risk group and might serve as therapeutic targets. Hindawi 2022-04-29 /pmc/articles/PMC9076319/ /pubmed/35528167 http://dx.doi.org/10.1155/2022/4010786 Text en Copyright © 2022 Cong Lu et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Lu, Cong Hu, Dong Zheng, Jin'e Cao, Shiyi Zhu, Jiang Chen, Xiangjun Huang, Shiang Yao, Junxia A Six-Gene Risk Model Based on the Immune Score Reveals Prognosis in Intermediate-Risk Acute Myeloid Leukemia |
title | A Six-Gene Risk Model Based on the Immune Score Reveals Prognosis in Intermediate-Risk Acute Myeloid Leukemia |
title_full | A Six-Gene Risk Model Based on the Immune Score Reveals Prognosis in Intermediate-Risk Acute Myeloid Leukemia |
title_fullStr | A Six-Gene Risk Model Based on the Immune Score Reveals Prognosis in Intermediate-Risk Acute Myeloid Leukemia |
title_full_unstemmed | A Six-Gene Risk Model Based on the Immune Score Reveals Prognosis in Intermediate-Risk Acute Myeloid Leukemia |
title_short | A Six-Gene Risk Model Based on the Immune Score Reveals Prognosis in Intermediate-Risk Acute Myeloid Leukemia |
title_sort | six-gene risk model based on the immune score reveals prognosis in intermediate-risk acute myeloid leukemia |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076319/ https://www.ncbi.nlm.nih.gov/pubmed/35528167 http://dx.doi.org/10.1155/2022/4010786 |
work_keys_str_mv | AT lucong asixgeneriskmodelbasedontheimmunescorerevealsprognosisinintermediateriskacutemyeloidleukemia AT hudong asixgeneriskmodelbasedontheimmunescorerevealsprognosisinintermediateriskacutemyeloidleukemia AT zhengjine asixgeneriskmodelbasedontheimmunescorerevealsprognosisinintermediateriskacutemyeloidleukemia AT caoshiyi asixgeneriskmodelbasedontheimmunescorerevealsprognosisinintermediateriskacutemyeloidleukemia AT zhujiang asixgeneriskmodelbasedontheimmunescorerevealsprognosisinintermediateriskacutemyeloidleukemia AT chenxiangjun asixgeneriskmodelbasedontheimmunescorerevealsprognosisinintermediateriskacutemyeloidleukemia AT huangshiang asixgeneriskmodelbasedontheimmunescorerevealsprognosisinintermediateriskacutemyeloidleukemia AT yaojunxia asixgeneriskmodelbasedontheimmunescorerevealsprognosisinintermediateriskacutemyeloidleukemia AT lucong sixgeneriskmodelbasedontheimmunescorerevealsprognosisinintermediateriskacutemyeloidleukemia AT hudong sixgeneriskmodelbasedontheimmunescorerevealsprognosisinintermediateriskacutemyeloidleukemia AT zhengjine sixgeneriskmodelbasedontheimmunescorerevealsprognosisinintermediateriskacutemyeloidleukemia AT caoshiyi sixgeneriskmodelbasedontheimmunescorerevealsprognosisinintermediateriskacutemyeloidleukemia AT zhujiang sixgeneriskmodelbasedontheimmunescorerevealsprognosisinintermediateriskacutemyeloidleukemia AT chenxiangjun sixgeneriskmodelbasedontheimmunescorerevealsprognosisinintermediateriskacutemyeloidleukemia AT huangshiang sixgeneriskmodelbasedontheimmunescorerevealsprognosisinintermediateriskacutemyeloidleukemia AT yaojunxia sixgeneriskmodelbasedontheimmunescorerevealsprognosisinintermediateriskacutemyeloidleukemia |